Skip to content
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
Prognostic value of radiological recurrence patterns in ovarian cancer.
Roze JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, Scholten RJPM, Zweemer RP.
Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219-5. doi: 10.1016/j.ygyno.2020.03.003. [Epub ahead of print]
Small Cell Carcinoma of the Ovary, Hypercalcaemic Type - genetics, new treatment targets and current management guidelines.
Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WPD, Huntsman DG, Lang JD, Orlando KA, Oza AM, Pautier P, Ray-Coquard I, Trent JM, Wichter M, Witkowski L, McCluggage WG, Levine DA, Foulkes WD, Weissman BE.
Clin Cancer Res. 2020 Mar 10. pii: clincanres.3797.2019. doi: 10.1158/1078-0432.CCR-19-3797. [Epub ahead of print]
Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family.
Sadzeviciene I, Jarmalaite S, Besusparis J, Liaugaudiene O, Asadauskiene J, Brasiuniene B, Kulikiene I, Sabaliauskaite R.
Medicina (Kaunas). 2020 Mar 10;56(3). pii: E119. doi: 10.3390/medicina56030119.
RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN.
Cancers (Basel). 2020 Mar 7;12(3). pii: E620. doi: 10.3390/cancers12030620.
How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors.
Neviere Z, De La Motte Rouge T, Floquet A, Johnson A, Berthet P, Joly F.
Ther Adv Med Oncol. 2020 Feb 28;12:1758835919897530. doi: 10.1177/1758835919897530. eCollection 2020.
Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.
Post navigation